To give a detailed characterization of pain in a large cohort of patients with Fabry disease.
In this single-center, retrospective study we performed a detailed analysis of pain prevalence and characteristics of 132 patients with Fabry disease. Data were obtained by screening all medical records and using standardized extraction forms. Missing data were completed by telephone interviews.
We show that men and women with Fabry disease frequently experience pain, mostly starting in early childhood. Pain is typically episodic with pain attacks being the predominant phenotype. The most frequent localization is in the distal extremities, the most often named pain quality is “burning.” Fabry pain is triggerable by physical activity and thermal stimuli and improves over time. Frequently used acute pain medication consists of nonsteroidal antirheumatics and nonopioid analgesics. Long-term medications such as drugs used to treat neuropathic pain syndromes are rarely taken by Fabry patients.
Pain in Fabry disease affects both sexes and has a complex phenotype that requires comprehensive assessment. Current pain questionnaires fail to cover the entire scope of Fabry pain. Although basically neuropathic, some types of Fabry pain may respond to nonsteroidal antirheumatics and nonopioid analgesics.
Supplemental Digital Content is available in the text.
*Department of Neurology
†Würzburg Fabry Center for Interdisciplinary Therapy (FAZIT), The University of Würzburg, Würzburg, Germany
Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website, www.clinicalpain.com.
Supported by an unrestricted grant from Genzyme Corporation, Neu Isenburg, Germany, to The University of Würzburg, Würzburg, Germany. The study is part of the doctoral thesis of S.G. N.Ü. received speaker honoraria from Genzyme Corp., Eczacibaşi-Baxter, Astellas; travel grants from Pfizer Inc., Eczacibaşi-Baxter, Genzyme Corp., Astellas, Grünenthal GmbH, CSL Behring. C.S. received speaker honoraria: Astellas, Baxter, CSL Behring, Genzyme Corp., GSK, Pfizer. The remaining authors declare no conflict of interest.
Reprints: Nurcan Üçeyler, MD, Department of Neurology, The University of Würzburg, Josef-Schneider-Str. 11, Würzburg 97080, Germany (e-mail: email@example.com).
Received April 2, 2013
Received in revised form October 23, 2013
Accepted September 30, 2013